RecruitingNCT06581549
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
Studying Malignant peritoneal mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Istituto Oncologico Veneto IRCCS
- Principal Investigator
- Giulia Pasello, MDIstituto Oncologico Veneto IOV IRCCS
- Intervention
- Translation analysis(other)
- Enrollment
- 220 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (10)
- Istituto Clinico Humanitas, Rozzano, Milano, Italy
- Centro di Riferimento Oncologico (CRO) IRCCS, Aviano, Pordenone, Italy
- Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
- Asst Papa Giovanni Xxiii Bergamo, Bergamo, Italy
- Ircss Ospedale Policlinico San Martino, Genova, Italy
- Asst Grande Ospedale Metropolitano Niguarda-Milano, Milan, Italy
- Fondazione Ircss Istituto Nazionale Dei Tumori Di Milano, Milan, Italy
- Istituto Oncologico Veneto, Padua, Italy
- Azienda Ospedaliera-Universitaria di Parma, Parma, Italy
- Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06581549 on ClinicalTrials.govOther trials for Malignant peritoneal mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07330271PTC-Guided Therapy for Peritoneal MesotheliomaBeijing Tsinghua Chang Gung Hospital
- RECRUITINGPHASE2NCT06543069Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPHASE2NCT06057935A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaMemorial Sloan Kettering Cancer Center